Michael Spreadborough – Executive Co-Chairman – NOVO Resources (ASX:NVO) is a gold explorer with one of the largest prospective gold and battery metals land packages in the Pilbara, a premier exploration and mining region located in Western Australia.
Copyright 2024 – Finance News Network
Source: Finance News Network
11 Nov 2022 - K2fly Limited (ASX:K2F) CEO Nic Pollock discusses K2F's progress and milestones over the past year.
Read More01 Jul 2022 - Shaw and Partners Chief Investment Officer Martin Crabb discusses market outlook and which sectors and stocks do well in a downturn.
Read More11 Sep 2019 - BluGlass Limited (ASX:BLG) Managing Director Giles Bourne discusses partnering with LED lighting developer Bridgelux, enabling smaller and cheaper LEDs, and what the future holds with BLG’s new facility.
Read More25 Aug 2021 - Shaw and Partners Chief Investment Officer Martin Crabb discusses reporting season and the lack of guidance from companies, cyclical businesses and M&A activity in the Energy sector.
Read More21 Jul 2021 - icetana (ASX:ICE) CEO and Managing Director Matt Macfarlane provides an update for the June quarter 2021.
Read More12 May 2021 - Galan Lithium (ASX:GLN) Managing Director Juan Pablo Vargas de la Vega provides an update on they company's key Hombre Muerto lithium brine project in the Catamarca province of Argentina.
Read More02 Jun 2022 - BluGlass Limited (ASX:BLG) Executive Chair James Walker provides an update on the company, discussing new staff and developments at BluGlass' manufacturing facility in Silicon Valley.
Read More31 Oct 2023 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses progress of the company's drug candidates, highlighting promising data from the 2023 ESMO Congress.
Read More29 Nov 2019 - Xplore Wealth Limited (ASX:XPL) CEO, Michael Wright, talks about the benefits of the company's non-aligned platform following the Hayne Royal Commission and key priorities for FY20.
Read More25 Oct 2023 - Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow discusses efficacy results for the company's glioblastoma therapy.
Read More
